Core Viewpoint - Zhenbaodao is accelerating the improvement of its traditional Chinese medicine industry chain layout through the acquisition of a 49% stake in Guizhou Shennong Valley, which will become a wholly-owned subsidiary of its subsidiary Bozhou Trading Center [1] Group 1: Acquisition Details - The acquisition amount is 490 million yuan, which includes the investment principal and interest from the fund during the investment period [1] - Guizhou Shennong Valley was established in August 2023 with a registered capital of 1 billion yuan [1] - As of March 31, 2025, Guizhou Shennong Valley has total assets of 1.062 billion yuan and net assets of 998 million yuan [1] Group 2: Financial Performance - In 2024, Zhenbaodao achieved revenue of 2.704 billion yuan, a year-on-year decrease of 13.84%, marking the lowest record in five years [2] - In the first quarter of 2025, the company reported a revenue decline of 58.03% to 469 million yuan and a net profit decline of 74.33% to 75.3 million yuan [2] - The decline in revenue and profit is attributed to the postponement of the third batch of national Chinese medicine procurement [2] Group 3: Product Development - On the same day as the acquisition announcement, Zhenbaodao received approval for clinical trials of its Fufang Qinlan Oral Liquid for children aged 4-12 [3] - The pediatric medication sector is experiencing significant policy benefits, and Fufang Qinlan Oral Liquid is positioned as a core product in Zhenbaodao's "anti-viral Chinese medicine matrix" [3] - The company’s total assets reached approximately 12.713 billion yuan by the end of 2024, with a year-on-year growth of 1.98% [3]

珍宝岛（603567）4月30日披露2024年年度报告，报告期内，公司实现营业收入27.04亿元，净利润4.38 亿元，基本每股收益0.47元。 另据公司同步披露的2025年第一季度报告，公司实现营业收入4.69亿元，净利润7529.54万元，基本每股 收益0.08元。 珍宝岛是一家综合性高端医药制药企业，业务涵盖药品研发创新、智能制造、全渠道营销、医药商业和 中药材产业。科技研发方面，公司以中成药为核心，兼顾化药、生物药协同发展，形成优势领域产品集 群。药品全渠道营销方面，公司已建立了涵盖全国30余省紧密型营销网络，构建了成熟、完备的营销管 理服务体系。 据珍宝岛2024年年报介绍，公司分别在哈尔滨、虎林、鸡西设有生产基地，共有21个生产车间，43条生 产线。截至报告期末，公司拥有170个生产文号，共计138个品种，其中86个品种进入2024年版国家医保 药品目录，涵盖35个甲类品种，51个乙类品种。同时，公司有31个品种被列入国家基药目录，拥有血栓 通胶囊、复方芩兰口服液和小儿热速清糖浆3个中药保护品种，以及复方芩兰口服液、血栓通胶囊、灵 芪加口服液和复方白头翁胶囊4个独家品种，形成了涵盖心脑血管、抗病毒 ...